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Abstract
Failure to adjust hypertension therapy despite elevated blood pressure (BP) levels is an important
contributor to lack of BP control. One possible explanation is that small elevations above goal BP
are not concerning to clinicians. BP levels farther above goal, however, should be more likely to
prompt clinical action. We reviewed one year’s worth of primary care records of 3,742 North
Carolina Medicaid recipients 21 years and older with hypertension (a total of 15,516 office visits)
to examine variations in hypertension management stratified by level of BP above goal and the
association of BP level above goal with documented anti-hypertensive medication change. Among
the 53% of patients not at goal BP, 42% were within 10/5 mm Hg of goal; 11% had a BP ≥40/20
mm Hg above goal. Higher level of BP above goal was independently associated with anti-
hypertensive medication change. Compared to visits at which BP was <10/5 mm Hg above goal,
the adjusted odds of medication change were 7.9 (95% CI 6.2-10.2) times greater at visits when
patients’ BP was ≥ 40/20 mm Hg above goal. However, even when BP was above goal at this
level, treatment change occurred only 46% (95% CI 40.2-51.8) of the time.
INTRODUCTION
Lack of control of elevated blood pressure (BP) represents an important public health
problem, responsible for considerable cardiovascular disease (CVD) morbidity and
mortality.1 Among the modifiable factors known to be associated with poor BP control,
suboptimal therapy is the most clinically important.2,3 In fact, most uncontrolled BP occurs
not among people with poor access to care, but rather among patients with known
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hypertension who have a usual source of care and who make regular clinic visits.4 The
failure of clinicians to initiate or intensify antihypertensive therapy despite elevated BP
levels has been termed clinical inertia5, and continued efforts are needed to overcome this
major impediment to achieving BP control.
One hypertension clinical action model conceptualizes clinical inertia as stemming from
four domains: organizational factors (e.g., sufficient support staff, access to follow-up),
competing demands and prioritization (e.g., patients with several comorbidities or multiple
complaints), medication related factors (e.g., number of medications, side effects), and
clinical uncertainty.6 Clinical uncertainty reflects the fact that a clinic BP can be a poor
gauge of a patient’s true BP status.
The domain of clinical uncertainty perhaps best encapsulates many of the reasons clinicians
use to avoid intensification of therapy or to explain but not act on an elevated clinic BP,
including that the BP goal has almost been reached.5-7 BP varies enough such that elevations
within 5 mm Hg or in some cases 10 mm Hg above goal noted on a single visit might be
viewed by clinicians in many instances as acceptable control, especially given that proper
BP measurement technique is often not followed in clinical practice. In addition, clinicians
may consider the commonness of the white-coat effect among treated hypertensives.8,9 The
view that “close to goal is good enough” may be especially true during visits for other
problems, particularly acute care visits unrelated to hypertension. However, higher
elevations of BP are more likely to indicate that BP is truly uncontrolled, should be more
concerning to clinicians, and therefore ought to prompt action by clinicians regardless of the
type of visit, particularly if BP has been elevated on one or more previous visits.
Using a statewide sample of primary care clinicians providing hypertension management to
Medicaid patients, we examined rates of BP control, hypertension management patterns, and
degree of BP elevation for patients with above-goal BP. We then examined the relationship
between degree of BP elevation above goal and documented changes in anti-hypertensive
therapy over the course of one year’s visits.
METHODS
Population and Sampling
Medicaid administrative data were used to select a representative sample of 3,742 NC
Medicaid recipients age 21 and older with hypertension managed in the primary care setting.
Recipients were enrolled with Medicaid for at least 11 months between July 1, 2005 and
June 30, 2006, and had an office visit with a diagnosis of hypertension (ICD9 401xx),
excluding pregnancy-induced hypertension. Patients who had any office visits with a
cardiologist or endocrinologist during this time were excluded, as were those receiving
dialysis services.
Primary care providers (PCPs) were identified according to Medicaid administrative data
and from professional services claims by clinicians of the following specialties: general or
family medicine, internal medicine, obstetrics/gynecology, and nurse practitioner. In
Medicaid administrative data, “provider” may refer to a single physician or a practice
organization. Therefore, the following practice types were also included in claims review for
PCP: federally qualified health center, health department, and rural health clinic. The
provider who had submitted the most claims (or the provider submitting the most recent
claim in the case of a tie) was identified as that patient’s PCP. Providers with fewer than five
patients in the population were excluded. For purposes of a quality improvement initiative
unrelated to this analysis, four sampling strata were used. Providers were selected at random
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from each of the four strata. Within randomly selected providers, all eligible charts were
reviewed.
Data Abstraction
Charts were reviewed in the offices of the PCPs. Only a small proportion of the practices
used an electronic medical record (EMR). Data from records were abstracted using an
electronic clinical data entry tool. Michigan Peer Review Organization developed the
abstraction tool in cooperation with NC Division of Medical Assistance (DMA). Colorado-
based Q Mark Inc. built the electronic abstraction tool and provided trained nurses for the
abstractions. A total of 4,046 charts were abstracted. Of these, 224 were excluded from
analysis because no hypertension diagnosis was found in the chart, and 80 were excluded
because no BP measurement was found subsequent to June 30, 2005. Data from charts of
3,742 patients seen by 160 PCPs were included in analysis. For visit-level analyses, detailed
information from up to the five most recent office visits made by the sample patients within
the preceding 12 months was abstracted.
Variables
Length of time with current PCP practice was calculated based on the earliest service date
and the most recent service date documented in the chart. PCP specialty was determined by
the self-identification of the billing practice as recorded in Medicaid administrative data.
Patient race was recorded from the chart abstracted. If race was not documented in the chart,
we used race as listed in the Medicaid Client Case files. The presence of other chronic
medical conditions was based on documentation of the diagnoses in the medical record. For
the variable “multiple chronic conditions”, congestive heart failure, coronary artery disease,
peripheral arterial disease and stroke/transient ischemic attack were all grouped as one
condition (cardiovascular disease). Similarly, substance abuse, depression, anxiety, and
other psychiatric disorders were counted as a single condition (mental illness); and chronic
obstructive pulmonary disease and asthma were counted as a single condition (respiratory
illness).
Study analyses were based on diagnoses, results, treatments and actions documented in the
medical records. BP treatment goals were defined as <130/80 mm Hg for patients with
diabetes, otherwise <140/90 mm Hg, in accordance with JNC7 guidelines.10 Above-goal BP
was categorized based on whichever measurement (systolic or diastolic) placed patient into
higher category. For example, a person categorized as having BP ≥20/10 mm Hg above goal
means that either the systolic BP (SBP) was ≥20 mm Hg above goal or the diastolic BP
(DBP) was ≥10 mm Hg above goal, or both. The most recent BP measurement noted in the
chart was used to determine level of control in patient-level analyses. For visit-level
analyses, provider response to elevated BP during the visit is based on information gathered
from the chart, usually noted in the “assessment and plan” portion of a visit note. In order to
attempt to account for visits at which a clinician might wait on further documented
elevations of BP before changing therapy, we also created a covariate to reflect the number
of prior visits during the study year at which BP was elevated. Provider responses to
elevated BP were noted as change in antihypertensive medication regimen, any documented
lifestyle recommendation, and/or plan for follow-up BP. We included provider responses of
addressing adherence in the lifestyle recommendation category. Visits were categorized as
chronic care visits or acute care/other visits based on the chief complaint or reason noted in
the chart for the visit. In the abstraction tool, acute visits were defined as visits of an
episodic nature with recently noted symptoms of a particular time frame (e.g., sore throat,
back pain for one month). Chronic visits were defined as visits recorded for follow-up of an
existing diagnosis (e.g., hypertension or diabetes), an annual physical exam, or a check such
as blood pressure check, blood sugar check, medication check or review.
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Data were analyzed using SAS version 9.2 (SAS Institute, Cary, North Carolina). Weights
were applied to reflect the unequal chance of being selected for providers in the different
strata (which were otherwise unrelated to this analysis). The 95% confidence intervals are
based on the weighted frequencies. For significance testing, the F-adjusted Rao-Scott chi
square test was used. After completing patient-level analyses to examine BP control rates
and general hypertension management, we conducted visit-level analyses to examine the
relationship of BP level above goal with documented changes in BP medication during that
office visit. We also examined the associations of several potential covariates with
documented BP medication changes. Bivariate relationships were tested using F-adjusted
Rao-Scott chi square. Variables associated at a p-value <0.10 with documented changes in
medication were placed into a multivariable logistic regression model to estimate their
independent contributions. Key variables of interest (sex and race) were retained in the
model.
This study was performed as part of a quality improvement activity of the NC DMA, and
exempted for review by the University of North Carolina Office of Human Research Ethics.
RESULTS
Characteristics of Patients in Analysis
A total of 3,742 patient charts were reviewed. Nearly 71% of patients were female (Table 1),
a proportion that is close to the 72% of adults eligible for Medicaid in North Carolina. Most
patients were ≥40 years, and approximately 52% of the patients were Black. Approximately
44% were current smokers. Obesity (60%) and diabetes (39%) were common, as was mental
illness or substance abuse (35%) and chronic pain (31%). Approximately 55% of patients
visited a family physician or general practitioner for their primary care; 30% visited an
internist. Approximately 90% of patients had continuity of care of at least one year with
their PCP, and almost 40% had continuity of care of five years or more.
Patient-Level Blood Pressure Control
Overall, BP was at goal in 47% (95% CI 44.6-49.7) of patients. BP was more than twice as
likely to be at goal among nondiabetics (60% vs 27%, p<0.0001) (Figure 1). Among the
53% of patients whose office BP was not at goal, 42% were within 10/5 mm Hg of their goal
BP (Table 2). Approximately 22% of patients whose BP was not at goal had a SBP 10-19
mm Hg or a DBP 5-9 mm Hg above goal; 18% had a SBP 20-29 mm Hg or DBP 10-14 mm
Hg above goal; 7% had a SBP 30-39 mm Hg or DBP 15-19 mm Hg above goal; and 11%
had a SBP ≥40 mm Hg or DBP ≥20 mm Hg above goal. In addition to being more likely to
have BP not at goal, diabetics were also more likely to have BP more than 20/10 mm Hg
above goal (28% vs 14%, p<0.0001) (Figure 1).
Among patients whose most recent BP was above goal, 36% (95% CI 32.3-40.4) had
elevation of SBP only, 17% (95% CI 14.2-20.7) had elevation of DBP only, and 46% (95%
CI 43.2-49.2) had elevations in both systolic and diastolic BP. Worth noting also is that 86%
(95% CI 83.5-88.0) of subjects with BP above goal at the most recent visit also had BP
above goal on at least one prior visit during the year, and 66% (95% CI 63.1-69.1) had a BP
above goal on at least two prior visits.
Documented Hypertension Management
Approximately 44% of the patients had documentation of lifestyle counseling over the
course of the preceding year (Table 3). The most commonly documented lifestyle
modifications were diet (28%) and exercise (21%). Weight reduction was documented as
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addressed in 14%, medication adherence in 11%, and sodium restriction in 9.3%. When
comparing the lifestyle modifications addressed stratified by level of BP control, the most
notable trend was in discussions of medication adherence. Such discussions were
documented for 6.9% of patients whose BP was at goal compared to 19% of those whose BP
was ≥20/10 mm Hg above goal.
Approximately 93% of the patients in this sample were on one or more antihypertensive
medications (Table 3). The most commonly prescribed drug classes were angiotensin
converting enzyme (ACE)-inhibitors (40%) and thiazide diuretics (40%). Calcium channel
blockers were prescribed for 31% and beta-blockers for 30%. Among patients with BP at
goal, 21% were prescribed three drug classes, and 14% were prescribed four or more drug
classes.
During the study period, the sample patients made 15,516 clinic visits for which BP level
above goal could be determined. Similar to the proportion of patients whose BP was
uncontrolled at their most recent visit, BP was above goal at 54%, or a total of 8228, of all
examined visits (Table 4). During visits (n=3321) when SBP was <10 mm Hg above goal or
DBP was <5 mm Hg above goal, at least one lifestyle recommendation (including
addressing adherence) was documented in 14%. During visits (n=1888) when SBP was
10-19 mm Hg above goal or DBP was 5-9 mm Hg above goal, a lifestyle recommendation
(including addressing adherence) was noted in 15%. Among visits (n=981) with a
documented SBP ≥40 mm Hg or DBP ≥20 mm Hg above goal, a lifestyle recommendation
(including addressing adherence) was documented in 20%.
At incrementally higher BP levels above goal, the proportion of visits at which patients
received a request for closer follow-up was greater. Among patient visits (n=981) with a
SBP ≥40 mm Hg or DBP ≥20 mm Hg above goal, 30% of patients were asked to follow-up
within two to four weeks and 11% within two weeks. Still, even with this degree of BP
elevation above goal, no follow-up plan was noted in 41% and no intervention or plan for
close follow-up was noted in 30% of such visits (data not shown).
Hypertension management and treatment adjustments were significantly different between
chronic care visits and acute/other care visits (Figure 2). For example, when SBP was 10-19
mm Hg above goal or DBP was 5-9 mm Hg above goal, a change in anti-hypertensive
medication regimen was noted in 16.2% of chronic care visits compared to 5.7% of acute/
other care visits (p<0.0001). At visits when BP was ≥40/20 mm Hg above goal, a change in
anti-hypertensive medication regimen was noted in 49% of chronic care visits compared to
32% of acute/other care visits (p=0.0006). Among these same visits, no BP follow-up plan
was noted in 36% of chronic care visits compared to 60% of acute/other visits.
Anti-hypertensive Medication Changes at Visits when BP Levels were Above Goal
Over the course of the patients’ 8,238 visits, a medication change was documented for 1,717
(weighted percent, 21.1%). In bivariate analyses, there was a clear direct relationship
between higher levels of BP elevation above goal and documented change in anti-
hypertensive medication regimen (Table 5). For example, among visits when the patient’s
BP level was <10/5 mm Hg above goal (n=3321), 11% had a documented medication
change, but among visits (n=981) when BP was ≥ 40/20 mm Hg above goal, 46% had a
documented medication change. Other factors associated with a documented change in BP
medication regimen were younger age group, non-obese BMI, not having diabetes, fewer
chronic conditions, higher number of prior visits with above goal BP, and chronic care visit.
Of note, sex, race, current tobacco use, time with PCP, and PCP specialty were not
associated with documented change in BP medication regimen.
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To further examine the effect of preceding visits on medication changes, we also compared
the percent of visits at which a medication change was documented when preceded by one
or two visits at which BP was elevated. Among visits (n=6,123) preceded by one visit with a
BP above goal, 14% had no documented BP medication change, and 23% had a documented
medication change. Among visits (n=4,193) preceded by two visits with BP above goal,
15% had no documented BP medication change, and 22% had a documented medication
change. Thus, while the percentage with a medication change was 1.5 times greater among
those with a preceding visit with an above goal BP compared to those with no preceding
visit above goal (p<0.0001), whether there was one preceding visit or two preceding visits
with an elevated BP made little difference.
In multivariable analysis, the factors associated with a documented change in anti-
hypertensive medication regimen were higher BP level above goal, younger age group, not
having diabetes, and chronic care visit (Table 6). Compared to a visit when BP was <10/5
mm Hg above goal, visits at which BP was ≥40/20 mm Hg above goal had 7.9 times the
odds of having a change in BP medication documented. Compared to BP-above-goal visits
among patients ≥65 years old, visits among patients 21-39 years of age had 1.8 times the
odds of having a BP medication change. BP-above-goal visits among patients who did not
have diabetes had nearly twice the odds of having a BP medication change documented.
Compared to acute care visits, chronic care visits at which BP was above goal had over
twice the odds of having a BP medication change documented. Number of prior visits above
goal and having multiple chronic conditions were no longer significant when controlling for
other effects.
DISCUSSION
Overall, we found BP to be controlled in approximately half of Medicaid patients in NC
with documented hypertension, and that much uncontrolled BP is within 10/5 mm Hg of
goal clinic BP. Over 1/3 of the patients with BP above goal in this sample had BP elevations
at least 20 mm Hg systolic or 10 mm Hg diastolic, levels that more than double the risk of
CVD complications.11 Existing therapeutic options have not been optimally utilized for
these: half were prescribed two or fewer antihypertensive drug classes, and only half had
any documented discussion of lifestyle recommendations or medication adherence during
the prior year. Despite multiple visits with elevated BP readings during the course of a year,
clinicians did not adjust therapy the majority of the time.
Not surprisingly, providers were more likely to change therapy at progressively higher levels
of clinic BP. However, a concerning point is that even among patients for whom the SBP
measurement was more than 40 mm Hg above goal, therapy was adjusted only half the time.
One could argue that with such extreme elevations, the clinician can be much more certain
that the patient’s BP is truly elevated and that the elevation cannot be “explained away”.
However, some degree of clinical inertia appears to be present even in the face of this near-
certainty. Therefore, other factors must play a role, and our study sheds some light on these
as well.
We found that uncontrolled BP was more often addressed by medication change at chronic
care visits than acute care visits, a relationship that was maintained after adjusting for other
factors. However, the association of change in medication with having fewer chronic
conditions was mitigated after adjusting for other factors (including type of visit). Another
recent study found that patients who had comorbidities unrelated to hypertension were less
likely to have uncontrolled hypertension addressed during a clinic visit.12 However, an
important distinction to make is that the conditions were unrelated to hypertension (such as
asthma, arthritis and gastroesophageal reflux), so would not include conditions such as heart
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disease and diabetes. Taken together, however, these findings still suggest that competing
demands unfortunately often trump hypertension management.
Among patients in our study sample with above-goal BP, over one-quarter were on
monotherapy, and a majority remained on fewer than three agents even at BP levels far
above goal. Clinicians may overestimate the BP-lowering effect achievable with any single
BP agent and may under-appreciate the fact, as demonstrated by clinical trials, that most
patients will need more than one class of antihypertensive drug to reach target BP, and many
patients will need at least three.13,14
We found that older patients were less likely to have their antihypertensive medication
adjusted. One possible explanation is that clinicians may underestimate the benefit of BP
control in older patients. It is also possible that clinicians view older age itself as a relative
contraindication to more aggressive BP control, or that concerns over reducing diastolic BP
too far limit clinicians’ willingness to up-titrate BP medications. However, while some
discretion must be used in lowering the diastolic BP below approximately 70 mm Hg in
patients with coronary artery disease, neither reason appears justified for most older
patients.15,16 We also found that diabetic patients were less likely to have BP medication
adjusted when their BP was above goal. Clinicians may not realize the importance of BP
control in diabetes, may accept lower degrees of control than recommended by national
guidelines, or perhaps spend more effort on achieving glycemic control.10,13-17-19
A strength of this study is that the sample is representative of a statewide Medicaid provider
population. It is worth noting that the patients in this study population are generally at higher
risk for CVD events and poor health outcomes by virtue of their lower socioeconomic status
and high prevalence of concomitant risk factors including diabetes and tobacco use.20
Therefore the difference between the actual care the patients are receiving and the improved
or ideal care they could receive is substantial in terms of avoidable CVD morbidity,
mortality, and health care costs, even in the short-term. Our estimates of BP control in this
population may actually be overestimates because patients with more complicated disease
(those seeing cardiologists and endocrinologists, those on dialysis) were excluded.
A limitation of this study is that our estimates of patient-level BP control are based on one
visit’s BP measurement(s), and the quality of the measurements (i.e., whether they were
conducted according to recommendations) are unknown. However, BPs at more than 80% of
the immediately preceding visits were also elevated. It is unlikely that alternative measures
of BP control would have altered our conclusions. It has been shown that the use of the
simplest approach, “last BP measurement recorded”, yields results similar to the use of a
threshold percent of visits with BP under control, or mean BP over time, for describing BP
control in a population.21 A further reason for considering control rates based on one visit is
that BP control as measured in quality measurement programs such as the National
Committee for Quality Assurance is based on the most recent clinic BP reading during the
measurement year.22
Our outcomes were based solely on chart documentation, so lifestyle recommendations and
discussions of medication adherence may have been under-estimated if not documented.
However, our main outcome of interest (BP medication change) should have been
appropriately documented in the medical record, and we therefore would have captured it.
We also acknowledge that BP medication change would not always mean intensification of
therapy.
However, alternative reasons for making a medication change (such as poor tolerability, side
effects or cost) would still be valid ways to address above-goal BP (because nonadherence is
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implied). We were unable to explore the degree to which provider uncertainty about patient
adherence to the prescribed medical regimen was associated with BP medication change, or
lack thereof.
The extent to which our findings are generalizable outside the Medicaid population is
uncertain, though overall rates of BP control in our study population were similar to mean
BP control rates reported by commercial health plans and Medicaid managed care
organizations nationally.23 Another consideration is that we included only patients with
diagnosed hypertension, and did not examine the proportion of Medicaid patients whose BP
is elevated but for whom hypertension remains undiagnosed (and therefore uncontrolled).
Regardless, our findings suggest ample opportunity for improving hypertension
management in the primary care setting. We are cognizant, however, that for Medicaid
recipients and others with multiple complex health care needs, treatment objectives may not
be achievable within predominant models of primary care practice.24 Hypertension
management approaches that involve non-physician personnel in team-based care and offer
patient self-management support and therapy intensification at more frequent intervals than
the traditional physician-patient encounter have proven to be some of the most
effective,25,26 but such approaches remain uncommon and may require substantial practice
redesign and payment reform for spread and sustainability.
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Blood Pressure at Goal and Uncontrolled ≥20/10 mm Hg above Goal, Overall and Stratified
by Diabetes Status
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Table 1








  Male 1,067 29.3 27.3-31.3
  Female 2,675 70.7 68.7-72.7
Age Groups
  21-39 years 628 16.6 14.5-18.7
  40-64 years 2,354 63.0 60.7-65.3
  65 years and over 760 20.4 17.6-23.3
Race Groups
  White 1,436 42.7 34.7-50.8
  Black 2,078 51.7 44.2-59.1
  Other or Unreported 228 5.6 4.0-7.2
Obesity (calculated BMI ≥30 kg/m2)*** 2,250 60.4 58.2-62.5
Diagnosed Comorbidities
  Diabetes 1,435 39.2 37.2-41.2
  Hyperlipidemia 1,622 44.4 41.5-47.3
  Coronary artery disease 347 9.7 8.0-11.4
  Congestive heart failure 200 5.8 4.5-7.0
  COPD or asthma 724 19.8 17.8-21.8
  Stroke or TIA 198 4.9 3.9-5.9
  Peripheral artery disease 64 1.6 1.1-2.2
  Mental illness or substance abuse 1,292 35.1 32.0-38.3
  Sleep apnea 142 4.0 3.0-5.0
  Chronic pain 1,159 30.5 27.1-33.8
Current Tobacco use 1,165 44.3 40.3-48.3
Multiple chronic conditions†
  0-1 2,111 55.4 52.7-58.1
  2-3 1,532 41.9 39.3-44.5
  4 or more 99 2.7 2.0-3.4
Length of time with current PCP#
  Less than 1 year 349 8.4 6.8-10.0
  1 - 2 years 1,268 32.4 27.4-37.4
  3 - 4 years 677 19.5 16.6-22.4
  5 or more years 1,332 39.8 34.2-45.4
PCP specialty
  General/Family Practice 1,944 54.9 40.6-69.2
  Internal Medicine 1,391 30.4 17.6-43.3
  Other/Unknown 407 14.7 5.9-23.5
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†
Chronic conditions include: diabetes, CVD (congestive heart failure, coronary artery disease, peripheral arterial disease, stroke, transient ischemic
attack), mental illness, chronic pain, chronic obstructive pulmonary disease/asthma.
#
For 116 patients, no first visit date was abstracted. Therefore, care period length with their provider could not be established.
**
Weighted Percent may not add up to 100 due to rounding.
***
Obesity prevalence estimate based on 3,663 patients with weight available. Abstracted height was used to calculate BMI for 2,124 patients. If
height was unavailable, gender specific median height of the study population was applied.
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Table 2




< 10/5 mm Hg above goal 809 42.0 39.2-44.8
10-19/5-9 mm Hg above goal 446 21.6 19.1-24.1
20-29/10-14 mm Hg above goal 349 18.2 16.5-20.0
30-39/15-19 mm Hg above goal 134 7.0 5.4-8.6
≥ 40/20 mm Hg above goal 222 11.2 9.6-12.8
*
Blood pressure at goal is defined as <130/80 mm Hg for patients with diabetes mellitus, for all others as <140/90 mm Hg.
**
Categorization in this table and throughout paper is based on whichever level (systolic or diastolic) placed patient into higher category.
For example, a non-diabetic patient with a BP of 152/81 mm Hg would be placed in the category of BP 10-19/5-9 mm Hg above goal
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Table 5
Unadjusted Associations between Patient Characteristics and Documented Change in Anti-Hypertensive
Medication(s) During Visits at Which Blood Pressure was Above Goal Over the Course of One Year
(n=8,238)
Characteristic N Weighted % P-Value‡
Total visits with medication change 1,717 21.1
BP level above goal* <0.0001
 < 10/5 mm Hg 393 11.4
 10-19/5-9 mm Hg 294 14.4
 20-29/10-14 mm Hg 404 29.2
 30-39/15-19 mm Hg 192 33.5
 ≥40/20 mm Hg 432 46.0
Sex 0.316
 Male 478 22.1
 Female 1,239 20.7
Age group 0.0002
 21-39 years 317 27.4
 40-64 years 1,071 20.6
 ≥65 years 329 18.4
Race group 0.239
 White 553 19.4
 Black 1,064 22.3
 Other 100 21.7
Obesity 0.020
 BMI < 30.0 kg/m2 624 23.5
 Obese 1,071 19.9
 BMI Unknown 22 18.2
Current Tobacco Use** 0.250
 No 682 21.6
 Yes 552 23.5
Diabetes <0.0001
 No 966 25.5
 Yes 751 17.4
Multiple chronic conditions <0.0001
 0-1 984 24.2
 2-3 692 18.5
 ≥4 41 12.9
Type of Visit <0.0001
 Chronic 1,543 19.8
 Acute/Other 174 20.6
Time with current PCP*** 22.9 0.303
 < 1 year 171 11.4
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Characteristic N Weighted % P-Value‡
 1-2 years 617 14.4
 3-4 years 295 29.2
 ≥5 years 535 33.5
Prior visits above goal 46.0
 0 visits 612 0.020
 1 visit 460 22.1
 ≥2 visits 645 20.7
PCP Specialty 0.858
 General/Family Practice 856 27.4
 Internal Medicine 668 20.6
 Other/Unknown 193 18.4
‡
F-adjusted Rao-Scott chi square p-value, unless otherwise noted.
*
The systolic or diastolic blood pressure value was missing for 10 visits; therefore, n for these analyses is 8,228.
**
Tobacco use among those screened: n=5,718. Medication change occurred for n=1,234.
***
For 256 visits, no first visit date of the patient to the current provider was abstracted. Therefore, time period with current provider could not be
established. Remaining n=7,982.
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Table 6
Adjusted Associations between Patient Characteristics and Documented Change in Anti-Hypertensive
Medication(s) During Visits at Which Blood Pressure was Above Goal Over the Course of One Year
(n=8,228*)
Characteristic N Odds Ratio 95% ConfidenceInterval
BP level above goal
 < 10/5 mm Hg 393 ref ref
 10-19/5-9 mm Hg 294 1.4 1.1 – 1.8
 20-29/10-14 mm Hg 404 3.4 2.8 – 4.1
 30-39/15-19 mm Hg 192 4.6 3.6 – 5.8
 ≥40/20 mm Hg 432 7.9 6.2 – 10.2
Sex
 Male 478 1.0 0.9 – 1.2
 Female 1,239 ref ref
Age group
 21-39 years 317 1.8 1.4 – 2.2
 40-64 years 1,071 1.3 1.1 – 1.6
 ≥65 years 329 ref ref
Race group
 White 553 ref ref
 Black 1,064 1.1 0.9 – 1.4
 Other 100 1.3 1.0 – 1.7
Obesity
 BMI lower than 30.0 624 1.3 0.7—2.5
 Obese 1,071 1.1 0.6—2.0
 BMI Unknown 22 ref ref
Diabetes
 Yes 751 ref ref
 No 966 1.9 1.6 – 2.3
Multiple chronic conditions
 0-1 984 ref ref
 2-3 692 0.9 0.8 – 1.1
 ≥4 41 0.6 0.4 – 1.0
Prior visits above goal
 0 visits 612 ref ref
 1 visit 460 1.0 0.8 – 1.1
 ≥2 visits 645 1.1 0.9 – 1.3
Type of Visit
 Acute/Other 174 ref ref
 Chronic 1,543 2.3 1.8 – 3.0
*
Number of observations used for this model is 8,228 because BP level above goal was missing for 10 visits. Number of visits with BP level above
goal and medication change is 1,715. ref, referent
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